XML 13 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Revenues:    
Net revenue - collaboration $ 63  
Net revenue - commercial product sales 1,196  
Revenue - bulk insulin sales 1,750  
Total revenues 3,009  
Expenses:    
Cost of goods sold 2,548 $ 5,168
Research and development 3,129 5,130
Selling, general and administrative 15,389 7,351
Loss on foreign currency translation 1,545 2,364
Total expenses 22,611 20,013
Loss from operations (19,602) (20,013)
Other income (expense):    
Change in fair value of warrant liability 6,629  
Interest income 55 15
Interest expense on notes (2,706) (4,221)
Interest expense on note payable to principal stockholder (714) (721)
Other income 14 67
Total other income (expense) 3,278 (4,860)
Loss before benefit for income taxes (16,324) (24,873)
Income tax benefit 0 0
Net loss $ (16,324) $ (24,873)
Net loss per share - basic and diluted $ (0.17) $ (0.29)
Shares used to compute basic and diluted net loss per share 95,744 85,772